Boston, MA -- (SBWIRE) -- 01/28/2014 -- At winstonsmallcap.com we focus on undervalued companies trading under $5. Right now the markets are surging and we are seeing an opportunity in micro-cap companies like we have never seen before. Let have a Look on: Northwest Biotherapeutics, Inc(NASDAQ:NWBO), YRC Worldwide, Inc.(NASDAQ:YRCW), AEterna Zentaris Inc. (USA)(NASDAQ:AEZS), Oramed Pharmaceuticals, Inc.(NASDAQ:ORMP)
Northwest Biotherapeutics, Inc(NASDAQ:NWBO) opened its shares at the price of $5.10 for the day. Its closing price was $5.00 after gaining +3.31% for the day. The company traded with the total volume of 2.73 million shares, while its average trading volume remained 805.735.00 shares. The beta of NWBO stands at 1.59. Northwest Biotherapeutics, Inc., a development stage biotechnology company, engages in discovering, developing, and commercializing immunotherapy products to treat cancers in the United States.
For How Long NWBO will Fight for Profitability? Read This Trend Analysis report
YRC Worldwide, Inc.(NASDAQ:YRCW) percentage change plunged -6.60% to close at $17.55 with the total traded volume of 2.71 million shares, and average volume of 2.02 million. The 52 week range of the stock remained $5.75 - $36.99, while its day lowest price was $16.26 and it hit its day highest price at $20.77. YRC Worldwide Inc., through its subsidiaries, provides various transportation services primarily in North America.
Has YRCW Found The Bottom And Ready To Gain Momentum? Find Out Here
AEterna Zentaris Inc. (USA)(NASDAQ:AEZS) started its trading session with the price of $1.30 and closed at $1.22 by scoring -5.43%. AEZS’s stocks traded with total volume of 2.70 million shares, while the average trading volume remained 2.85 million shares. The beta of AEZS stands at 1.37. Day range of the stock was $1.21 -$1.30. Aeterna Zentaris Inc. (NASDAQ: AEZS) is a specialty biopharmaceutical company engaged in developing novel treatments in oncology and endocrinology. The Company's pipeline encompasses compounds from drug discovery to regulatory approval. Its lead oncology program is an ongoing Phase 3 trial in endometrial cancer with zoptarelin doxorubicin (formerly AEZS-108). Its lead endocrinology product is macimorelin acetate (formerly AEZS-130) for which an NDA has been submitted to the FDA, seeking approval for the marketing and sales of macimorelin acetate as the first orally-administered product that induces growth hormone release to evaluate Adult Growth Hormone Deficiency (AGHD). Its pipeline also encompasses other earlier-stage programs in both oncology and endocrinology.
Why Should Investors Buy AEZS After the Recent Fall? Just Go Here and Find Out
Oramed Pharmaceuticals, Inc.(NASDAQ:ORMP) ended its day with the gain of +21.90% and closed at the price of $24.38 after opening at $20.86. Stock traded during its last trading session with the total volume of 2.56 million shares, as compared to its average volume of 921,428.00 shares. Oramed Pharmaceuticals, Inc., a development stage pharmaceutical company, is engaged in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides.
Why Should Investors Buy ORMP After The Recent Gain? Just Go Here and Find Out
Here at Winston we focus on undervalued companies trading under $5. Right now the markets are surging and we are seeing an opportunity in micro-cap companies like we have never seen before. We focus on companies that we feel are trading at a discount to the market for various reasons. Enter your email and track our performance! We are sure you won’t be disappointed.
http://winstonsmallcap.com/ and its owners, and their affiliates, directors and officers, and immediate family members, are hereafter collectively referred to as “WSC” or “we” or “us” or “our”). WSC publishes information (the “Information”) about publicly traded companies (the “Profiled Company” or the “Profiled Companies”) which has been obtained from various sources including publicly available sources on the internet. WSC does not undertake any due diligence or investigation of the Information it obtains or publishes.
Read Full Disclaimer at: http://winstonsmallcap.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)